Second U.S. Patent Awarded to Alvalux for Wearable Light Therapy Device

 Alvalux Medical, a Belgian medtech wearables company, has been awarded its second Patent from the U.S. Patent and Trademark Office for its wearable ocular insert device.
 
The invention (U.S. Patent 10,953,240) is a small, energized, ocular insert designed to deliver home-based photobiomodulation (PBM) therapy to treat retinal diseases including age-related macular degeneration and diabetic retinopathy which affect approximately 20 million people in the United States alone.
 
“This patent represents an important contribution to the future of ‘on-eye’ miniaturized therapeutic wearables, and it also spawned two other inventions including our on-market, award-winning, CicaLux product line,” said Michel Alvarez, CEO and inventor. “I would like to congratulate co-inventor—professor Denis Flandre—ICTEAM institute at the Université catholique de Louvain (UCLouvain) for his contribution and shared vision to bring smart, small, wearable, home-therapy devices to people around the world.”
 
“This was a great basis for our deeper collaboration and further innovation in smart medical wearables involving ultra-low-power thin-film electronic circuits and sensors,” said Professor Flandre.
 
Alvalux’s first patent award, announced in March (U.S. Patent 10,953,238) is a wearable dermal repair system marketed under the CicaLux brand that delivers energized combination PBM therapy to treat various skin-related conditions, diseases and disorders. First product CicaLux Energized Scar-Care is available for sale in the European Union, United States and other countries. 
 
Alvalux Medical is a Belgian-based medical device company founded in 2015 by medtech veteran Michel Alvarez. It aims to be a global leader in smart, wearable, energized, therapeutic devices for use at home, at work, or on the go.